Aspen Neuroscience Prices $140.6M Nasdaq IPO

Aspen Neuroscience priced its initial public offering at $15.00 a share on 29 October 2026, selling 9,375,000 shares for $140.6 million gross before underwriting discounts and expenses. The San Diego, California company began trading the next morning on the Nasdaq Global Select Market under the ticker ASPE, with proceeds earmarked largely for a planned Phase 3 trial of sasineprocel, its autologous, patient-derived cell therapy for Parkinson's disease.

Named for a mountain, built on a biopsy

From $6.5 million to $140.6 million

1. 2018

   Founded in San Diego

   Jeanne Loring, a stem-cell biologist then at the Scripps Research Institute, co-founds Aspen Neuroscience with lab colleague Andrés Bratt-Leal and Ashley Van Zeeland, building on Loring’s Parkinson’s research and the patient advocacy of the Summit for Stem Cell Foundation; a $6.5 million seed round follows, led by Domain Associates and Axon Ventures.

2. March 2020

   $70 million Series A

   OrbiMed leads a Series A round to move the company’s lead candidate, then called ANPD001, toward the clinic.

3. 25 Jan 2021

   Damien McDevitt named CEO

   McDevitt, previously CEO of Akcea Therapeutics (acquired by Ionis Pharmaceuticals in 2020), joins Aspen Neuroscience as President and Chief Executive Officer.

4. 9 May 2022

   $147.5 million Series B

   OrbiMed, ARCH Venture Partners, Frazier Life Sciences and Revelation Partners co-lead a Series B round as the therapy heads toward human testing.

5. 19 Oct 2023

   FDA Fast Track designation

   ANPD001 receives Fast Track designation for Parkinson’s disease.

6. 17 Apr 2024

   First patient dosed

   Aspen doses the first patient in ASPIRO, the open-label Phase 1/2a trial of ANPD001 (NCT06344026).

7. November 2025

   $115 million Series C

   OrbiMed, ARCH, Frazier and Revelation return to lead a Series C, bringing Aspen’s total capital raised past $340 million, including an $8 million California Institute for Regenerative Medicine grant.

8. 30 Jun 2026

   15 patients dosed

   Aspen completes dosing of ASPIRO’s third and fourth cohorts, bringing the trial’s total to 15 patients.

9. 30 Jul 2026

   FDA RMAT designation

   The therapy, now named sasineprocel, receives Regenerative Medicine Advanced Therapy designation based on ASPIRO’s early safety and engraftment data.

10. 29–30 Oct 2026

    Nasdaq IPO priced, trading begins

    The offering prices at $15.00 a share for $140.6 million gross; shares begin trading the next morning on the Nasdaq Global Select Market.

11. H2 2027

    Planned Phase 3 dosing

    Aspen anticipates dosing the first Phase 3 patients, pending FDA alignment on the pivotal study’s design.

What $140.6 million buys sasineprocel next

The registration statement Aspen Neuroscience filed with the U.S. Securities and Exchange Commission on 9 October 2026, as later amended, directed roughly $8 million of the offering toward completing ASPIRO, the ongoing Phase 1/2a trial of sasineprocel, and roughly $110 million toward a Phase 3 program for the same candidate, with a further $4 million toward an earlier-stage autologous microglia research program — figures the company disclosed against a $150 million target before the offering priced at the bottom of its range for $140.6 million. Aspen has not published a revised breakdown for the smaller, final total, so a reader should treat the original split as directional rather than final.

Before the offering, Aspen's registration statement carried the standard disclosure that, absent additional financing, substantial doubt existed about the company's ability to continue as a going concern — a line common to pre-revenue biotechs ahead of the financing meant to resolve it. The company has booked no product revenue; secondary reporting on the prospectus put its net loss at roughly $66.8 million for the twelve months ended 30 June 2026.

“This significant milestone highlights the transformative nature of sasineprocel as a potentially disease-modifying therapy for patients facing a serious disease with substantial unmet medical need.” Damien McDevitt, PhD, President and Chief Executive Officer, Aspen Neuroscience — 30 July 2026, on FDA's RMAT designation for sasineprocel (not a statement about the IPO itself)

Sasineprocel's IPO, in four figures

$140.6Mgross IPO proceeds from 9,375,000 shares at $15.00 apiece

15Parkinson's patients dosed with sasineprocel in the Phase 1/2a ASPIRO trial as of 30 June 2026

2FDA designations held by sasineprocel: Fast Track (Oct 2023) and RMAT (Jul 2026)

H2 2027when Aspen anticipates dosing the first patients in a planned Phase 3 trial

Figures from Aspen Neuroscience's SEC filings and its 29–30 October 2026 IPO pricing and prior clinical and regulatory announcements.

One patient's skin, grown into dopamine neurons

Sasineprocel starts with a skin biopsy. Aspen reprograms a patient's own skin cells into induced pluripotent stem cells, then differentiates them into dopaminergic neuron precursor cells — the cell type that dies off in the brains of people with Parkinson's disease — before delivering them by stereotactic, image-guided injection into the putamen, the brain region most affected by the disease. Because the cells come from the same patient who receives them, Aspen says the therapy does not require the immunosuppression that an off-the-shelf, donor-derived cell therapy would need — the central bet behind the company's autologous approach, and one its allogeneic competitors do not share.

Three bets behind sasineprocel's design

01

Autologous, not off-the-shelf

Each dose is manufactured from the patient who will receive it, which Aspen says removes the need for the lifelong immunosuppression that donor-derived (allogeneic) competitors require — at the cost of a bespoke, patient-specific manufacturing process rather than a batch-produced one.

02

Two FDA designations, one trial

Sasineprocel holds both Fast Track (October 2023) and RMAT (July 2026) designations, both based on data from the same ASPIRO trial. RMAT is reserved for regenerative therapies with early evidence of treating a serious condition, and it opens the door to more frequent FDA interaction on trial design.

03

Fifteen patients, no serious surgical complications reported

Across ASPIRO's first four cohorts, Aspen has reported FDOPA PET imaging showing cell survival and engraftment, and no serious surgical adverse events, graft-induced dyskinesia or symptomatic hemorrhage — safety data from a small, uncontrolled, open-label trial that a sham-controlled Phase 3 will still have to confirm.

Where a rival is already approved

No cell replacement therapy for Parkinson's disease is approved in the United States. Sasineprocel's nearest rival by mechanism, bemdaneprocel from BlueRock Therapeutics (a Bayer subsidiary), is further along on paper: it also holds RMAT designation and has entered a sham-surgery-controlled Phase 3 trial, exPDite-2, built on allogeneic iPSC-derived dopamine neuron precursors that, unlike sasineprocel, require immunosuppression. In Japan, Sumitomo Pharma and Kyoto University's CiRA have gone further still: their own allogeneic iPS-cell-derived dopaminergic progenitor therapy won conditional regulatory approval there, marketed as Amchepry, on data from seven patients treated at Kyoto University Hospital — a conditional approval that still requires the company to collect further results to support full approval, and one outside experts have described as resting on comparatively thin, uncontrolled evidence.

A Parkinson's market no cell therapy has priced yet

$3.4B → $7.0B

Parkinson's disease treatment market across the U.S., five major European markets and Japan, 2023 to 2033, as forecast by GlobalData — a figure for all Parkinson's treatments combined, not cell therapy alone, since no cell therapy for the disease is yet approved in that market.

2023$3.4B

2033$7.0B

2032 (SNS Insider)$8.75B

Sources: GlobalData, Parkinson's Disease: Seven Market Drug Forecast and Market Analysis, 2025 update · SNS Insider, Parkinson's Disease Treatment Market Report, November 2025

Regulatory News outlook

We expect cell therapies for Parkinson's disease — sasineprocel among them, if its Phase 3 trial succeeds — to remain a small slice of a market still dominated by levodopa and other drug and device therapies through the early 2030s, worth well under a billion dollars in combined global sales by 2030.

How we got here: GlobalData's $7.0 billion 2033 figure for all Parkinson's treatment spending, if cell therapies capture even a 5% share once more than one is approved — a conservative share given only one, in Japan, is conditionally approved anywhere today — implies roughly $350 million in combined cell-therapy sales by the early 2030s; sasineprocel's piece of that depends on Phase 3 data still years away.

Sasineprocel against the Parkinson's cell-therapy field

Program	Cell source	Stage	Immunosuppression
Sasineprocel (Aspen Neuroscience)	Autologous (patient's own skin cells)	Phase 1/2a (RMAT, Fast Track); Phase 3 planned H2 2027	Not required, per the company
Bemdaneprocel (BlueRock Therapeutics / Bayer)	Allogeneic (donor-derived iPSCs)	Phase 3 (exPDite-2, sham-controlled)	Required
CT1-DAP001 / Amchepry (Sumitomo Pharma / Kyoto University CiRA)	Allogeneic (donor-derived iPSCs)	Conditionally approved in Japan; further data collection ongoing	Required

From each company's or institution's own disclosures and public trial registrations; not a clinical comparison. No autologous cell therapy for Parkinson's disease is approved anywhere.

What has to go right before H2 2027

Aspen's own account of its timeline leaves the hardest step ahead of it: agreeing with FDA on how a pivotal trial for a one-time, surgically delivered cell therapy should be controlled. The company has said it expects FDA may favor a sham-surgery control — a design that would require Parkinson's patients in the control arm to undergo a placebo brain procedure — while Aspen has argued a natural-history comparison could work instead. Which design FDA accepts will shape both the trial's cost and how persuasive its eventual results are.

• Trial design: FDA alignment on a Phase 3 design — sham-controlled surgery or a natural-history comparator — is still pending.
• Offering close: the IPO was expected to close 2 November 2026, subject to customary conditions, with underwriters holding a 30-day option on up to 1,406,250 additional shares.
• Manufacturing: each dose of sasineprocel is made to order from an individual patient's cells, a process Aspen's Series C financing was partly meant to help scale.
• Competing designs: BlueRock's bemdaneprocel is already in a sham-controlled Phase 3, and Sumitomo's allogeneic therapy has conditional approval in Japan — sasineprocel is the only autologous entrant among the three, a difference that complicates mass manufacturing but, Aspen argues, avoids immune rejection.

What this IPO does not resolve: whether FDA will accept a sham-controlled or a natural-history Phase 3 design, what that trial will show once it reads out, or whether a patient-specific manufacturing process can scale to the price and volume a commercial cell therapy would need. Those answers are years away; Friday's listing buys the company the runway to pursue them.

Frequently asked questions

How much did Aspen Neuroscience raise in its IPO?

$140.6 million gross, before underwriting discounts and expenses, after the offering priced at $15.00 a share for 9,375,000 shares on 29 October 2026 — the bottom of its marketed $15–$17 range. Underwriters hold a 30-day option on up to 1,406,250 additional shares, and the offering was expected to close 2 November 2026.

What is sasineprocel?

An investigational, autologous cell therapy for Parkinson's disease, formerly called ANPD001. Aspen reprograms a patient's own skin cells into induced pluripotent stem cells, differentiates them into dopaminergic neuron precursor cells, and delivers them by image-guided injection into the brain. It holds FDA Fast Track and RMAT designations and remains investigational; no cell therapy for Parkinson's disease is approved in the United States.

When will Aspen start a Phase 3 trial?

The company anticipates dosing the first patients in the second half of 2027, pending further discussion with FDA over the pivotal trial's design, including whether it will require a sham-surgery control arm.

Is Aspen Neuroscience profitable?

No. The company has not generated product revenue and secondary reporting on its IPO prospectus put its net loss at roughly $66.8 million for the twelve months ended 30 June 2026. Its pre-IPO filings disclosed substantial doubt about its ability to continue as a going concern absent additional financing, which this offering was intended to address.

Who else is developing a cell therapy for Parkinson's disease?

BlueRock Therapeutics, a Bayer subsidiary, is testing bemdaneprocel, an allogeneic (donor-derived) iPSC-based therapy, in a sham-controlled Phase 3 trial. In Japan, Sumitomo Pharma and Kyoto University's CiRA have won conditional approval for a similar allogeneic therapy, marketed as Amchepry. Both require immunosuppression; sasineprocel, being autologous, is designed not to.